Research Analysts Issue Forecasts for REGN FY2025 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Stock analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Wednesday, February 5th. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings per share of $29.37 for the year, down from their previous estimate of $38.93. Cantor Fitzgerald has a “Neutral” rating and a $1,015.00 price objective on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $37.75 per share.

A number of other research analysts have also weighed in on the stock. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Citigroup reduced their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Finally, Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Trading Up 0.7 %

Shares of REGN stock opened at $722.07 on Friday. The company has a 50 day moving average of $717.27 and a 200-day moving average of $914.93. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $642.00 and a 12-month high of $1,211.20. The firm has a market cap of $79.35 billion, a P/E ratio of 17.87, a PEG ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the business posted $11.86 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently bought and sold shares of REGN. State Street Corp increased its stake in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. International Assets Investment Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company’s stock valued at $495,639,000 after buying an additional 22,538 shares during the last quarter. Swiss National Bank grew its holdings in shares of Regeneron Pharmaceuticals by 0.6% during the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after buying an additional 2,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after buying an additional 1,108 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date of this dividend is Thursday, February 20th.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.